Division of Medical Oncology
University of Colorado Denver
12801 E. 17th Avenue
Aurora, CO 80010
Ph: (303) 724-3888
Fax: (303 724-3889 info@deptofmed.edu
Rene Gonzalez, M.D.
Professor
Education: University of Honduras
Tegucigalpa – 1981
University of Colorado Denver
School of Medicine
Division of Medical Oncology
Tel: (303) 724-3888
Fax: (720) 848-058
e-mail: rene.gonzalez@uchsc.edu
Bio
Dr Gonzalez has been at UCHSC since 1986.
Research
Dr. Gonzalez is Professor of Medicine and of Dermatology and Director of the Melanoma Research Clinics at the University of Colorado Health Sciences Center (UCHSC). This comprehensive program includes multi-disciplinary oncology clinics and tumor board. Dr Gonzalez’s clinical interests are malignant melanoma and other cutaneous malignancies; his research interests focus on conventional and experimental treatment of melanoma. Dr. Gonzalez is the principal investigator on numerous national and local therapeutic trials. He is a member of several professional societies including the American Society of Clinical Oncology, the International Society for Biologic Therapy of Cancer, and the Society for Melanoma Research. He has authored or coauthored several book chapters and more than 100 articles and abstracts that have been published in peer-reviewed journals or presented at national or international conferences or symposia.
Publications
McCarter MD, Baumgartner J, Escobar GA, Richter D, Lewis K, Robinson W, Wilson C, Palmer BE, Gonzalez R.: Immunosuppressive Dendritic and Regulatory T Cells are Upregulated in Melanoma Patients. Ann Surg Oncol. 14(10):2854-60. 2007.
Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, Walpole ET, Haydon AMM, Creese BR, Roberts KL, Zalcberg JR, Gonzalez R: A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs. 2007 Sep 20
Lewis KD, Robinson WA, McCarter M, Pearlman N, O’Day S, Anderson C, Amatruda TT, Baron A, Zeng C, Becker M, Dollarhide S, Matijevich K, Gonzalez R: A Phase II, Multicenter Study Of Neoadjuvant Biochemotherapy For Patients With Stage III Malignant Melanoma. J. Clin. Oncol 26(19) 3157-3163, 2006.